Oxymatrine

DB16276InvestigationalSmall molecule

Oxymatrine is under investigation in clinical trial NCT02202473 (Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects).

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor alpha, Inosine-5'-monophosphate dehydrogenase 2, and Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₁₅H₂₄N₂O₂ · 264.369 g/mol (avg)

Resolves to

Compound

UNII85U4C366QSCAS16837-52-8

Structure

InChIKeyXVPBINOPNYFXID-JARXUMMXSA-NSMILES[H][C@]12CCC[N@@+]3([O-])CCC[C@]([H])([C@@]4([H])CCCC(=O)N4C1)[C@]23[H]

Targets

Q07869PPARAP12268IMPDH2P00533EGFRP19838NFKB1Q14145KEAP1

What you can answer from here — as of September 15, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Oxymatrine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account